SpecimenSeq™ AML
BMMCs and PBMCs
The SpecimenSeq™ BMMCs and PBMCs inventory report contains:
- 33,589 detections of 52 specific genes
- 65 unique AML and MDS patients
- 21 of the patient cases include matched BMMCs + PBMCs
Inventory Request Submission:
- Download and review the inventory report.
- Highlight your samples of interest and save the report.
- Submit the saved inventory report file via the contact form linked below, along with any additional details or requests.
Conduct Smarter Oncology R&D Faster With SpecimenSeq™
Overview:
Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. SpecimenSeq makes this challenge easier for hematological oncology developers by delivering access to fully consented, ethically collected BMMCs and PBMCs characterized with the Illumina TruSight Myeloid Panel.
SpecimenSeq™
Deliverables &
Characterization
AML BMMCs and PBMCs
BMMCs, PBMCs, and BMMCs + PBMCs Matched Sets
| Biospecimen Format | Characterization reports |
|---|---|
| BMMCS | • Clinical information and pathology report • Qiagen’s Clinical Insights (QCI) pipeline report • Previous treatment information (if applicable) • Flow Cytometry characterization (if available) |
| PBMCS | • Clinical information and pathology report • Qiagen’s Clinical Insights (QCI) pipeline report • Previous treatment information (if applicable) |
| BMMCS + PBMCS | • Clinical information and pathology report • Qiagen’s Clinical Insights (QCI) pipeline report • Previous treatment information (if applicable) • Flow Cytometry characterization (if available) |
NGS Characterization
| TRUSIGHT MYELOID SEQUENCING PANEL GENE LIST | ||||
|---|---|---|---|---|
| ABL1 | CEBPA | HRAS | MYD88 | SF3B1 |
| AKT1 | CSF3R | IDH1 | NOTCH1 | SMC1A |
| ATRX | CUX1 | IDH2 | NPM1 | SMC3 |
| BCOR | DNMT3A | IKZF1 | NRAS | SRSF2 |
| BCORL1 | ETV6/TEL | JAK2 | GPDGFRA | STAG2 |
| BRAF | EZH2 | JAK3 | PHF6 | TET2 |
| CALR | FBXW7 | KDM6A | PTEN | TP53 |
| CBL | FLT3 | KIT | PTPN11 | U2AF1 |
| CBLB | GATA1 | KRAS | RAD21 | WT1 |
| CBLC | GATA2 | MLL | RUNx1 | ZRSR2 |
| CDKN2A | GNAS | MPL | SETBP1 | |
NGS results are delivered via a Qiagen Clinical Insights (QCI) report that includes:
- Genomic variants that have been shown to have clinical relevance
- Pathogenicity and level of clinical significance according to clinical guidelines
- Predicted protein changes
- Relevant drug treatments or resistance to drugs based on the genetic variants
- Relevant active clinical trials for patients that would harbor the same genomic variants as were identified in the biospecimen sample
Additional characteristics are available through our expert, integrated service laboratories.
IHC Services
Cell Services
Applications:
Biomarker
Discovery
Verification of the presence of biomarker targets in your populations of interest
Assessing
Mutations
Confirmation of driver mutations and other clinically relevant genomic variants in viable BMMCs and PBMCs
Oncology
Therapeutics
Acceleration of timelines for identifying responders versus non-responders and efficacy evaluations for new cancer therapies
To propel your projects with The Power of Discovery.™
Contact Us Today
Let us know about your project!
